Pharmaniaga Berhad Balance Sheet Health
Financial Health criteria checks 1/6
Pharmaniaga Berhad has a total shareholder equity of MYR-150.2M and total debt of MYR1.2B, which brings its debt-to-equity ratio to -820.8%. Its total assets and total liabilities are MYR2.1B and MYR2.3B respectively. Pharmaniaga Berhad's EBIT is MYR208.1M making its interest coverage ratio 3.1. It has cash and short-term investments of MYR66.4M.
Key information
-820.8%
Debt to equity ratio
RM 1.23b
Debt
| Interest coverage ratio | 3.1x |
| Cash | RM 66.43m |
| Equity | -RM 150.17m |
| Total liabilities | RM 2.30b |
| Total assets | RM 2.15b |
Recent financial health updates
No updates
Recent updates
Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry
Jul 18
Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S
May 09Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate
Apr 19Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price
Oct 03Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?
Jul 19Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?
Feb 18Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital
Dec 10Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts
Nov 24We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings
Aug 27Financial Position Analysis
Short Term Liabilities: PHARMA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: PHARMA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: PHARMA has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: PHARMA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: PHARMA's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: PHARMA's interest payments on its debt are well covered by EBIT (3.1x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 07:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharmaniaga Berhad is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hsien Jin Lam | CGS International |
| Yee Low | Hong Leong Investment Bank Berhad |
| Ping-Khoon Choo | Kenanga Research |